NCT04388072

Brief Summary

The diagnostic cohort study could will be use to verify the clinical performance of the AQP4 -immunoglobulin G detection kit and whether it has a good correlation with the clinical diagnosis results. The applicability and accuracy of the kit in clinical diagnosis will be verified according to the measured data.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2020

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 10, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 14, 2020

Completed
1 day until next milestone

Study Start

First participant enrolled

May 15, 2020

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2021

Completed
Last Updated

February 3, 2022

Status Verified

January 1, 2022

Enrollment Period

7 months

First QC Date

May 10, 2020

Last Update Submit

January 19, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • results of AQP4 -immunoglobulin G detection kit

    The Serum test results of participants using AQP4 -immunoglobulin G detection kit

    through study completion, an average of 6 months

Eligibility Criteria

Age14 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with NMOSD who are diagnosied in the First Affiliated Hospital of Fujian Medical Universtiy by two neurolgists

You may qualify if:

  • The patients who were diagnosed with NMOSD , and the cell-based assay was used to determine the AQP4-IgG-seropositive patients;
  • AQP4-IgG is negative in health people with age and sex matching and determined by cell-based assay;
  • Female or male, age 14-80;
  • Patients or authorized family members volunteered to participate in this study and signed informed consent.

You may not qualify if:

  • Patients with coagulation disorders;
  • Infection-related encephalitis;
  • Immune-related encephalitis;
  • A patient with severe mental illness who cannot cooperate clinically;
  • A patient with severe jaundice.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Department of Neurology,First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, 350005, China

Location

Third Affiliated Hospital of Sun Yat-sen University

Guangzhou, China

Location

MeSH Terms

Conditions

Neuromyelitis Optica

Condition Hierarchy (Ancestors)

Myelitis, TransverseDemyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesOptic NeuritisOptic Nerve DiseasesCranial Nerve DiseasesDemyelinating DiseasesEye DiseasesAutoimmune DiseasesImmune System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

May 10, 2020

First Posted

May 14, 2020

Study Start

May 15, 2020

Primary Completion

December 1, 2020

Study Completion

February 20, 2021

Last Updated

February 3, 2022

Record last verified: 2022-01

Locations